Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lorin S et al. – The results identify JNK as a novel mediator of DRAM regulation. These findings suggest that 2–ME or other anticancer therapies that increase DRAM expression or function could be used to effectively treat sarcoma patients.

Related Articles

Primary Ewing's sarcoma of the frontal bone with intracranial extension
Journal of Cancer Research and Therapeutics, 10/27/09    Relevance Score: 69%

Isolated CNS vasculitis: Unusual presentation of relapsed Ewing sarcoma
Pediatric Blood & Cancer, 11/12/09    Relevance Score: 68%

Cell cycle inhibition and apoptosis induced by curcumin in Ewing sarcoma cell line SK-NEP-1
Medical Oncology, 11/04/09    Relevance Score: 66%

Histological heterogeneity of Ewings sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support
Virchows Archiv, 10/27/09    Relevance Score: 66%

Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel
Journal of Pediatric Hematology/Oncology, 11/06/09    Relevance Score: 65%

Today in Basic Science/Genetics...keeping you current

EphA2 in the Early Pathogenesis and Progression of Non–Small Cell Lung Cancer
Cancer Prevention Research, 12/09/09

Effects of Chlorophyll and Chlorophyllin on Low-Dose Aflatoxin B1 Pharmacokinetics in Human Volunteers
Cancer Prevention Research, 12/09/09

Dynamic Gene Expression Analysis Links Melanocyte Growth Arrest with Nevogenesis
Cancer Research, 12/09/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address